These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 31137625)

  • 1. Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy.
    Soundararajan R; Fradette JJ; Konen JM; Moulder S; Zhang X; Gibbons DL; Varadarajan N; Wistuba II; Tripathy D; Bernatchez C; Byers LA; Chang JT; Contreras A; Lim B; Parra ER; Roarty EB; Wang J; Yang F; Barton M; Rosen JM; Mani SA
    Cancers (Basel); 2019 May; 11(5):. PubMed ID: 31137625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversing an Oncogenic Epithelial-to-Mesenchymal Transition Program in Breast Cancer Reveals Actionable Immune Suppressive Pathways.
    Williams MM; Hafeez SA; Christenson JL; O'Neill KI; Hammond NG; Richer JK
    Pharmaceuticals (Basel); 2021 Nov; 14(11):. PubMed ID: 34832904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
    Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
    Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
    Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
    Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma.
    Lou Y; Diao L; Cuentas ER; Denning WL; Chen L; Fan YH; Byers LA; Wang J; Papadimitrakopoulou VA; Behrens C; Rodriguez JC; Hwu P; Wistuba II; Heymach JV; Gibbons DL
    Clin Cancer Res; 2016 Jul; 22(14):3630-42. PubMed ID: 26851185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanoparticle Delivery of TWIST Small Interfering RNA and Anticancer Drugs: A Therapeutic Approach for Combating Cancer.
    Glackin CA
    Enzymes; 2018; 44():83-101. PubMed ID: 30360816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective Targeting of Protein Kinase C (PKC)-θ Nuclear Translocation Reduces Mesenchymal Gene Signatures and Reinvigorates Dysfunctional CD8
    Dunn J; McCuaig RD; Tan AHY; Tu WJ; Wu F; Wagstaff KM; Zafar A; Ali S; Diwakar H; Dahlstrom JE; Bean EG; Forwood JK; Tsimbalyuk S; Cross EM; Hardy K; Bain AL; Ahern E; Dolcetti R; Mazzieri R; Yip D; Eastgate M; Malik L; Milburn P; Jans DA; Rao S
    Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Checkpoint Blockade Therapy for Breast Cancer: Lessons from Epithelial-Mesenchymal Transition.
    O'Connell I; Dongre A
    Mol Diagn Ther; 2023 Jul; 27(4):433-444. PubMed ID: 37193859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rational combination of immunotherapy for triple negative breast cancer treatment.
    Li CW; Lim SO; Hsu JL; Hung MC
    Chin Clin Oncol; 2017 Oct; 6(5):54. PubMed ID: 29129094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in Molecular Mechanisms and Immunotherapy Involving the Immune Cell-Promoted Epithelial-to-Mesenchymal Transition in Lung Cancer.
    De Matteis S; Canale M; Verlicchi A; Bronte G; Delmonte A; Crinò L; Martinelli G; Ulivi P
    J Oncol; 2019; 2019():7475364. PubMed ID: 31531020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.
    Vilariño N; Bruna J; Bosch-Barrera J; Valiente M; Nadal E
    Cancer Treat Rev; 2020 Sep; 89():102067. PubMed ID: 32682248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a natural small-molecule compound that suppresses tumor EMT, stemness and metastasis by inhibiting TGFβ/BMP signaling in triple-negative breast cancer.
    Di L; Liu LJ; Yan YM; Fu R; Li Y; Xu Y; Cheng YX; Wu ZQ
    J Exp Clin Cancer Res; 2019 Mar; 38(1):134. PubMed ID: 30898152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion.
    Jiang Y; Zhan H
    Cancer Lett; 2020 Jan; 468():72-81. PubMed ID: 31605776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Facts and Perspectives: Implications of tumor glycolysis on immunotherapy response in triple negative breast cancer.
    Schreier A; Zappasodi R; Serganova I; Brown KA; Demaria S; Andreopoulou E
    Front Oncol; 2022; 12():1061789. PubMed ID: 36703796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SIRT1 induces tumor invasion by targeting epithelial mesenchymal transition-related pathway and is a prognostic marker in triple negative breast cancer.
    Jin MS; Hyun CL; Park IA; Kim JY; Chung YR; Im SA; Lee KH; Moon HG; Ryu HS
    Tumour Biol; 2016 Apr; 37(4):4743-53. PubMed ID: 26515337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
    Madden DL
    Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
    Thomas R; Al-Khadairi G; Roelands J; Hendrickx W; Dermime S; Bedognetti D; Decock J
    Front Immunol; 2018; 9():947. PubMed ID: 29770138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lactate Metabolism and Immune Modulation in Breast Cancer: A Focused Review on Triple Negative Breast Tumors.
    Naik A; Decock J
    Front Oncol; 2020; 10():598626. PubMed ID: 33324565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer/Testis Antigens: Expression, Regulation, Tumor Invasion, and Use in Immunotherapy of Cancers.
    Salmaninejad A; Zamani MR; Pourvahedi M; Golchehre Z; Hosseini Bereshneh A; Rezaei N
    Immunol Invest; 2016 Oct; 45(7):619-40. PubMed ID: 27603913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.